Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
05/2003
05/27/2003CA2173105C Protease-containing cleaning compositions
05/27/2003CA2140866C Use of inhibitors of fatty acid synthesis for treating cancer
05/27/2003CA2131168C Decontaminating blood components
05/27/2003CA2110119C Antiinflammatory and analgesic gel preparation
05/27/2003CA2104297C 4-sulfanimide-quinoline nmda antagonists
05/27/2003CA2084961C Tissue protective tocopherol analogs
05/27/2003CA2066104C Benzazepine derivatives as vasopressin antagonists
05/22/2003WO2003042660A2 Screening method for predicting susceptibility to breast cancer
05/22/2003WO2003042404A2 Breast cancer eradication program
05/22/2003WO2003042358A2 Methods of using 48149, a human aminopeptidase family member
05/22/2003WO2003042344A2 Apo2 ligand/trail formulations
05/22/2003WO2003042251A1 Chitosan compositions
05/22/2003WO2003042228A1 Macrolides
05/22/2003WO2003042219A1 Novel c-3 s/o- and s/n formaldehe acetal derivatives of cephalo sporins and their use as antibiotics
05/22/2003WO2003042218A1 Novel compounds
05/22/2003WO2003042216A1 Polycyclic guanine derivative phosphodiesterase v inhibitors
05/22/2003WO2003042214A2 A2b adenosine receptor antagonists
05/22/2003WO2003042213A1 Substituted tetracyclic pyrroloquinolone derivatives useful as phosphodiesterase inhibitors
05/22/2003WO2003042211A1 Phenyl substituted triazoles and their use as selective inhibors of akl5 kinase
05/22/2003WO2003042210A1 Azabicyclic-phenyl-fused-heterocyclic compounds and their use as alpha7 nachr ligands
05/22/2003WO2003042208A1 Pyrazole derivatives as psychopharmaceuticals
05/22/2003WO2003042207A1 Thiazolyl substituted triazoles as alk5 inhibitors
05/22/2003WO2003042205A1 Piperidine derivatives and their use as modulators of chemokine receptor activity (especially ccr5)
05/22/2003WO2003042204A1 Amine derivative
05/22/2003WO2003042194A1 Carboxylic acid derivative compounds and drugs containing the same as the active ingredient
05/22/2003WO2003042191A1 Benzamide and heteroarylamide as p2x7 receptor antagonists
05/22/2003WO2003042190A1 N-alkyl-adamantyl derivatives as p2x7-receptor antagonists
05/22/2003WO2003042188A1 Triazole derivative and medicinal composition containing the same
05/22/2003WO2003042186A1 Dithiocarbamate derivatives and their use as antibacterial agents
05/22/2003WO2003042184A1 Benzimidazol- or indol-aminoacetonitrile derivatives for parasite control
05/22/2003WO2003042182A1 Monohydroxycarbamazepine for use in the preparation of a medicament for the treatment of affective and attention disorder and neuropathic pain
05/22/2003WO2003042179A1 Heterocyclic derivatives of glycinamide and their medical use
05/22/2003WO2003042178A1 Novel piperidine derivatives as modulators of chemokine receptors
05/22/2003WO2003042177A1 Piperidine derivatives and their use as modulators of chemokine receptor activity (especially ccr5)
05/22/2003WO2003042176A1 Azabicyclo compound, matrix metalloprotease inhibitor, and skin preparation
05/22/2003WO2003042175A1 Sulphonamide derivatives, the preparation thereof and the application of same as medicaments
05/22/2003WO2003042174A1 Cannabinoid receptor ligands
05/22/2003WO2003042173A1 Nk1 antagonists
05/22/2003WO2003042172A2 C-5 modified indazolylpyrrolotriazines
05/22/2003WO2003042171A1 Vitamin d derivatives with acyloxy groups at the 24-position of the side chain, a method for producing the same and use thereof in production of medicaments
05/22/2003WO2003042165A1 Formoterol tartrate process and polymorph
05/22/2003WO2003042164A1 Aryl aniline beta-2 adrenergic receptor agonists
05/22/2003WO2003042162A1 Prodrugs of antidepressants and their use for treating depressions
05/22/2003WO2003042161A1 Venlafaxine hydrochloride polymorphs
05/22/2003WO2003042150A1 Novel bensophenone derivatives or salts thereof
05/22/2003WO2003042147A1 Dihalogenpropene compounds, method for the production thereof, agents containing said compounds and the use thereof as pest control agents
05/22/2003WO2003041756A1 Endoluminal devices coated with latrunculin to prevent ingrowth of cells
05/22/2003WO2003041754A1 Medical devices having antimicrobial coatings thereon
05/22/2003WO2003041743A1 Aspirin-containing transdermal pharmaceutical composition for the treatment of calcification
05/22/2003WO2003041741A1 Method of preventing or treating benign gynaecological disorders
05/22/2003WO2003041740A1 Tumor necrosis agent
05/22/2003WO2003041739A1 Anticaner agents
05/22/2003WO2003041736A2 Method for the treatment of cardiotoxicity induced by antitumor compounds
05/22/2003WO2003041727A2 Plant derived or derivable material with appetite suppressing activity
05/22/2003WO2003041724A1 Use of a mixture of sodium hyaluronate and chondroitin sulfate for the treatment of osteoarthritis
05/22/2003WO2003041723A1 Pharmaceutical applications of hyaluronic acid preparations
05/22/2003WO2003041722A1 Use of specific dose of fondaparinux sodium for the treatment of acs
05/22/2003WO2003041721A1 Process for reacting alkaloids and use of the reaction products in the preparation of medicaments
05/22/2003WO2003041720A1 Pharmaceutical composition based on micronized progesterone, preparation method and uses thereof
05/22/2003WO2003041719A1 Method of contraception in mammalian females and pharmaceutical kit for use in such method
05/22/2003WO2003041718A1 Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy
05/22/2003WO2003041717A1 Persistent filmy preparation for topical administration containing prostaglandin derivative
05/22/2003WO2003041716A1 Dosage unit comprising a prostaglandin analog for treating constipation
05/22/2003WO2003041715A1 Substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
05/22/2003WO2003041714A1 Benzotriazepines as gastrin and cholecystokinin receptor ligands
05/22/2003WO2003041713A1 Use of therapeutic dosages for nitric oxide donors which do not significantly lower blood pressure or pulmonary artery pressure
05/22/2003WO2003041712A1 Pyridone, pyridazone and triazone derivatives as lp-pla2 inhibitors
05/22/2003WO2003041711A1 Piperazine bis-amide derivatives and their use as antagonists of the orexin receptor
05/22/2003WO2003041710A1 Methods for preventing or treating disease mediateb by toxin-secreting bacteria
05/22/2003WO2003041709A1 Compositions and methods of treating iron excess
05/22/2003WO2003041708A1 Benzimidazoles useful as protein kinase inhibitors
05/22/2003WO2003041707A1 N-adamantylmethyl derivates and intermediates as pharmaceutical compositions and processes for their preparation
05/22/2003WO2003041706A1 Pharmaceutical composition comprising a glitazone and a thiazolidinedione derivative, and use thereof for treating diabetes
05/22/2003WO2003041705A1 Oral dosage form of a sulfonamide prodrug such as parecoxib
05/22/2003WO2003041704A1 Preventive or remedy for pruritus
05/22/2003WO2003041703A2 Use of a flavonoid for the treatment of burns
05/22/2003WO2003041702A1 Production of pure stereoisomers of tricyclo[5.2.1.02.6]-dec-9-yl xanthogenate and medicaments therefrom
05/22/2003WO2003041701A2 Preparation for improving the action of receptors
05/22/2003WO2003041700A1 Storage stable thyroxine active drug formulations
05/22/2003WO2003041699A1 Storage stable thyroxine active drug formulations and methods for their production
05/22/2003WO2003041698A1 Amino acid-containing tablets quickly disintegrating in the oral cavity and process for producing the same
05/22/2003WO2003041697A1 Method for treating autoimmune diseases
05/22/2003WO2003041696A1 Methods and compositions for use of (s)-bisoprolol
05/22/2003WO2003041695A1 Method and pharmaceutical preparations for reducing the activity of cells
05/22/2003WO2003041694A2 Use of compounds comprising iodine, strontium and ascorbic acid as well as either bismuth, zinc or potassium in the treatment of aids
05/22/2003WO2003041693A1 Delivery of diazepam through an inhalation route
05/22/2003WO2003041692A1 Extended release compositions comprising as active compound venlafaxine hydrochloride
05/22/2003WO2003041690A2 Three-dimensional suspension printing of dosage forms
05/22/2003WO2003041688A1 Methods for treatment of inflammatory diseases
05/22/2003WO2003041687A2 Method for producing stable solutions of phenolic substances and resulting solutions
05/22/2003WO2003041686A2 Improved therapy for topical diseases
05/22/2003WO2003041684A2 Injectable depot compositions and uses thereof
05/22/2003WO2003041683A2 Orodispersible tablets containing fexofenadine
05/22/2003WO2003041681A2 Lipid carrier compositions with enhanced blood stability
05/22/2003WO2003041680A1 Topical compositions containing enzymes stabilized with inhibitors
05/22/2003WO2003041678A1 Carotenoid composition and method for protecting skin
05/22/2003WO2003041675A2 Utilization of sterols and their derivatives in cosmetic and dermatological preparations for uva protection
05/22/2003WO2003041669A1 A composition for promoting hair growth
05/22/2003WO2003041660A2 Solubilized topoisomerase poisons
05/22/2003WO2003041654A2 Anti-estrogen and immune modulator combinations for treating breast cancer
1 ... 5458 5459 5460 5461 5462 5463 5464 5465 5466 5467 5468 5469 5470 5471 5472 5473 5474 5475 5476 5477 5478 ... 7860